Pullen Investment Management LLC Trims Stock Position in Kenvue Inc. $KVUE

Pullen Investment Management LLC decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 61.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,298 shares of the company’s stock after selling 52,463 shares during the quarter. Pullen Investment Management LLC’s holdings in Kenvue were worth $574,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in KVUE. Van ECK Associates Corp raised its position in Kenvue by 101.3% in the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after acquiring an additional 9,240,434 shares during the period. American Century Companies Inc. grew its position in shares of Kenvue by 22.4% during the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after acquiring an additional 6,781,640 shares during the period. Amundi grew its position in shares of Kenvue by 82.5% during the 2nd quarter. Amundi now owns 14,509,890 shares of the company’s stock valued at $305,446,000 after acquiring an additional 6,559,261 shares during the period. Mondrian Investment Partners LTD purchased a new stake in shares of Kenvue in the 3rd quarter worth $79,269,000. Finally, Alliancebernstein L.P. increased its stake in shares of Kenvue by 115.9% in the 2nd quarter. Alliancebernstein L.P. now owns 6,438,473 shares of the company’s stock worth $134,757,000 after purchasing an additional 3,456,204 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.1%

Shares of Kenvue stock opened at $17.16 on Friday. The company has a market capitalization of $32.90 billion, a P/E ratio of 22.29, a P/E/G ratio of 3.89 and a beta of 0.61. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The company has a fifty day moving average of $17.98 and a 200 day moving average of $17.08. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $3.68 billion. During the same period last year, the firm earned $0.26 earnings per share. The business’s quarterly revenue was up 3.2% on a year-over-year basis. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Analyst Ratings Changes

Several research firms recently weighed in on KVUE. Barclays lifted their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Friday, March 6th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Canaccord Genuity Group lifted their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Finally, Citigroup increased their target price on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.